Rising Incidence of Lung Cancer to Demand Lung Cancer Biopsy Market

The global lung cancer liquid biopsy market is anticipated to grow at a significant CAGR of 13.4% during the forecast period (2024-2031). The increasing lung cancer incidence and growing demand for non-invasive diagnostic methods along with ongoing  technological advancements is  a key factor driving the growth of the global market. According to the National Library of Medicine, in January 2023, lung cancer was observed as one of the cancers with the highest incidence rate and the second-highest mortality rate in the world. Moreover, according to the American Cancer Society, lung cancer (both small cell and non-small cell) is the second most common cancer in both men and women in the US (not counting skin cancer). The American Cancer Society’s estimates for lung cancer in the US for 2024 are:

Browse the full report description of “Lung Cancer Liquid Biopsy Market Size, Share & Trends Analysis Report by Biomarker (Circulating Nucleic Acids, CTC, Exosomes/Microvesicles, Circulating Proteins), by Application (Therapy Selection, Treatment Monitoring, Early Cancer Screening, Recurrence Monitoring), by End-User(Hospitals and Laboratories, Specialty Clinics, Academic and Research Centers), by Product (Instruments, Consumables Kits and Reagents, Software and Services) Forecast Period (2024-2031)” at https://www.omrglobal.com/industry-reports/lung-cancer-liquid-biopsy-market

• About 234,580 new cases of lung cancer (116,310 in men and 118,270 in women)

• About 125,070 mortalities from lung cancer (65,790 in men and 59,280 in women)

In December 2022, Agilent Technologies Inc. received FDA approval for Agilent Resolution ctDx FIRST as a companion diagnostic used to identify advanced non-small lung cancer in patients. The ongoing FDA approval for instruments used in lung cancer liquid biopsy treatment is further contributing to the global market growth.

Market Coverage

• The market number available for – 2023-2031

• Base year- 2023

• Forecast period- 2024-2031

• Segment Covered- 

o By Applications

o By Biomarker

o By-Products

o By End - User

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

Competitive Landscape-Eurofins Scientific Corp., Thermo Fisher Scientific Inc., Qiagen NV, and Exact Sciences Corp. among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Lung Cancer Liquid Biopsy Market Report Segment

By Application

• Therapy Selection
• Treatment Monitoring
• Early Cancer Screening
• Recurrence Monitoring

By Biomarker

• Circulating Nucleic Acids
• CTC
• Exosomes/Microvesicles
• Circulating Proteins

By End-User

• Hospitals and Laboratories
• Specialty Clinics
• Academic and Research Centers

By Products

• Instruments
• Consumables Kits and Reagents
• Software and Services

Global Lung Cancer Liquid Biopsy Market Report Segment by Region

North America

• United States

• Canada

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/lung-cancer-liquid-biopsy-market